Dave Damrau
About Dave Damrau
Dave Damrau is the Head of Regional Clinical Operations - Americas at Bristol Myers Squibb, with over a decade of experience in clinical operations and business management within the pharmaceutical industry.
Current Title at Bristol Myers Squibb
Dave Damrau serves as the Head of Regional Clinical Operations for the Americas at Bristol Myers Squibb. In this role, he oversees clinical operations within the American regions, guiding strategic initiatives and ensuring the efficient execution of clinical trials.
Previous Roles at Bristol Myers Squibb
Dave Damrau has held several leadership roles at Bristol Myers Squibb. Between 2019 and 2022, he was the Executive Director of GDO Operations in Lawrenceville, NJ. Prior to this, he served as the Director of Business Operations Lead from 2018 to 2019, also based in Lawrenceville, New Jersey. His tenure at Bristol Myers Squibb has been marked by significant responsibilities in managing various aspects of business and clinical operations.
Career at Novo Nordisk
Before joining Bristol Myers Squibb, Dave Damrau accumulated extensive experience at Novo Nordisk, Inc. His roles included Director of Operational Execution and Associate Director of CTM Planning and Analysis in Princeton, NJ. Additionally, he held positions such as Manager of Business Management, Lead CRA, and Senior In-house CRA over a span of more than six years. Throughout his time at Novo Nordisk, Dave progressively took on more senior roles, contributing to the company's clinical trial management and operational strategies.
Educational Background
Dave Damrau holds a Bachelor's degree in Biochemistry and Molecular Biology from Rutgers University. This academic foundation has supported his career in clinical operations and business management within the pharmaceutical industry.
Experience in Pharmaceutical Industry
Dave Damrau possesses over a decade of experience in clinical operations and business management within the pharmaceutical industry. He has demonstrated expertise in operational execution and clinical trial management, particularly through his leadership roles at Bristol Myers Squibb and extensive tenure at Novo Nordisk. His career transition from Novo Nordisk to Bristol Myers Squibb in 2018 highlights his capability in taking on significant responsibilities and leading various strategic initiatives.